ARK Genomic Revolution ETF vs Build A Bear Workshop Inc — how do they compare? ARK Genomic Revolution ETF trades at $44.29, while Build A Bear Workshop Inc trades at $36.88 (market cap $467.15M). The key difference: Build A Bear Workshop Inc pays a 2.47% dividend while ARK Genomic Revolution ETF pays none, and ARK Genomic Revolution ETF is trading nearer its 52-week high, Build A Bear Workshop Inc nearer its low. Which is the better fit depends on your goals.
| ARKG | BBW | |
|---|---|---|
Sector | Sector/Thematic | Consumer Cyclical |
52-Week High | $44.55 | $75.85 |
52-Week Low | $24.02 | $29.84 |
Market Cap | — | $467.15M |
Enterprise Value | — | $566.59M |
Dividend Yield | — | 2.47% |
Signals from Pluang's Aura AI — not financial advice
ARKG, the ARK Genomic Revolution ETF, trades at $43.04, up 6.06% in the past 24 hours, with a bullish technical signal from moving averages and ADX indicators. The ETF focuses on small- and mid-cap biotech stocks, with its top 10 holdings comprising 59% of the portfolio and a long-term EPS growth rate of 10.7%. Recent news highlights its recovery from a 15% correction, with support emerging at key levels.
The outlook for ARKG is positive, driven by biotech sector tailwinds including a friendlier FDA, strong M&A activity, and AI-driven drug discovery. Risks include high concentration in volatile biotech names and sensitivity to broader market sell-offs. Investors should weigh the growth potential against the inherent volatility of genomics investments.
Build-A-Bear Workshop (BBW) trades at $36.86, up 6.19% today, with a bullish technical signal and strong analyst support. The stock exhibits attractive valuation metrics, including a P/E of 8.73 and P/S of 0.92, alongside robust profitability with a 10.48% net income margin and 35.87% ROE. Recent earnings have consistently beaten estimates, and the company maintains a debt-free balance sheet while executing a growth strategy focused on international expansion and brand partnerships.
The outlook for BBW is positive, driven by earnings momentum and a consensus price target of $62.50 implying significant upside. Key risks include near-term consumer spending volatility and execution of expansion plans, but strong fundamentals and shareholder returns via dividends support a favorable risk-reward profile for long-term investors.
Trailing returns across standard periods
ARKG is an actively managed ETF that invests in the genomic revolution. It focuses on companies leading in gene editing, CRISPR technology, therapeutics, and molecular diagnostics, including firms like CRISPR Therapeutics and Tempus AI.
Read more on ARKG →Build-A-Bear is a global retailer specializing in customizable stuffed animals. It offers an interactive make-your-own experience where customers choose, stuff, and dress their furry friends in-store or online.
Read more on BBW →